FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 518 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Alternatives for Outdoor Foods October 16, 2020 Combination of Azacitidine and Venetoclax in Previously Untreated AML August 18, 2020 5 Tips to Move Beyond the Bedside May 17, 2021 Uncle Charlie’s Promise February 23, 2021 Load more HOT NEWS Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... A Cancer Revolution comes to Manchester: Patrick’s review What People With Breast Cancer and Survivors Should Know About Exercising... After Spine Tumor, Teacher Goes On Mission To Serenade Hospital Patients...
